BioSpace News Archive

Rigel Pharmaceuticals, Inc. announced one oral and four poster presentations at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain being held June 13-16, 2024, and online.

Pfizer Inc. announced detailed overall survival results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ in patients with heavily pretreated relapsed or refractory multiple myeloma.

Kite, a Gilead Company, announced results from three new analyses for Yescarta® in relapsed/refractory large B-cell lymphoma, including both new clinical research and real-world evidence highlighting manufacturing and product characteristics of Yescarta, and outpatient administration of both Yescarta and Tecartus® at the 2024 European Hematology Association Annual Congress, June 13-16, Madrid.

Venus Medtech, a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced that its in-house developed innovative transcatheter pulmonic valve replacement system, VenusP-Valve, has completed its first implantation in the PROTEUS IDE Pivotal Clinical Study at the University of Virginia School of Medicine.

Greenwich LifeSciences, Inc. announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale of 174,825 shares of its common stock at a purchase price of $14.30 per share in a private placement.

Enveda Biosciences, a biotechnology company using AI to translate nature into new medicines, announced a new financing round of $55 million to add to its $119 million combined Series B and B1.

Generation Bio Co. announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the virtual 2024 TD Cowen Genetic Medicines & RNA Summit on Friday, June 21st, 2024 at 1:50 p.m. ET.

Invivyd, Inc. announced that VYD222, a half-life extended investigational monoclonal antibody, shows continued in vitro neutralization activity in pseudovirus assays designed to represent the predominant emerging variants of SARS-CoV-2, including the KP.1.1 FLiRT and KP.3 variants.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, shared new clinical data from its ongoing KT-333 Phase 1 trial.

Editas Medicine, Inc., a clinical-stage genome editing company, announced new safety and efficacy data in 18 patients living with sickle cell disease treated with renizgamglogene autogedtemcel in the Phase 1/2/3 RUBY clinical trial.